Proteomics

Dataset Information

0

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy


ABSTRACT: To investigate the contribution of fibroblast-derived extracellular matrices (ECMs) to the resistance to targeted therapies in BRAF-mutated melanoma cells, we generated native-like 3D ECMs from human primary fibroblasts obtained from healthy individuals or melanoma patients. Cell-derived matrices from human dermal fibroblasts (HDF), skin melanoma associated fibroblasts (MAF) and two different lymph node fibroblast reticular cells (FRC) were denuded of cells and their composition was analyzed by mass spectrometry.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Fibroblast

DISEASE(S): Skin Cancer

SUBMITTER: AUDEBERT Stephane  

LAB HEAD: Deckert Marcel

PROVIDER: PXD026645 | Pride | 2021-11-12

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Garlau_Rep1.raw Raw
Garlau_Rep1_180830201633.raw Raw
Garlau_Rep1_180830225548.raw Raw
Garlau_Rep2_180903003222.raw Raw
Garlau_Rep2_180903031139.raw Raw
Items per page:
1 - 5 of 38
altmetric image

Publications


Resistance to BRAF/MEK inhibitor therapy in BRAF<sup>V600</sup> -mutated advanced melanoma remains a major obstacle that limits patient benefit. Microenvironment components including the extracellular matrix (ECM) can support tumor cell adaptation and tolerance to targeted therapy; however, the underlying mechanisms remain poorly understood. Here, we investigated the process of matrix-mediated drug resistance (MMDR) in response to BRAF<sup>V600</sup> pathway inhibition in melanoma. We demonstrat  ...[more]

Similar Datasets

2022-09-22 | PXD019869 | Pride
2012-07-19 | E-GEOD-39475 | biostudies-arrayexpress
2010-08-24 | E-GEOD-23764 | biostudies-arrayexpress
2018-12-30 | E-MTAB-4965 | biostudies-arrayexpress
2018-12-31 | E-MTAB-4964 | biostudies-arrayexpress
2020-08-31 | PXD020426 | Pride
2016-08-09 | E-GEOD-72619 | biostudies-arrayexpress
2025-08-22 | PXD054010 | Pride
2022-06-23 | PXD031223 | Pride
2023-07-11 | PXD041660 | Pride